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BACKGROUND: To evaluate the safety and efficacy of dose-dense weekly chemotherapy in the treatment of advanced thymoma.
METHODS: Subjects comprised patients with histologically documented chemotherapy-naı ¨ve thymoma with stage-IVa or IVb disease.
Thymic carcinoma, carcinoid or lymphoma cases were excluded. Patients received 9 weeks of chemotherapy: cisplatin (25mgm
 2)
on weeks 1–9; vincristine (1mgm
 2) on weeks 1, 2, 4, 6 and 8; and doxorubicin (40mgm
 2) and etoposide (80mgm
 2) on days
1–3 of weeks 1, 3, 5, 7 and 9. Chemotherapy courses were supported by granulocyte colony-stimulating factor. Post-protocol local
therapy was allowed.
RESULTS: From July 1997 to March 2004, 30 patients were entered. Three were ineligible due to different histology. Chemotherapy-
associated toxicity was mainly haematological and was well tolerated, with no deaths due to toxicity, and 87% of patients completed
the planned 9-week regimen. Overall response rate was 59%, with 16 of the 27 eligible patients achieving partial response. Median
progression-fee survival (PFS) was 0.79 years (95% confidence interval: 0.52–1.40 years), and PFS at 1 and 2 years was 37 and 15%,
respectively. Overall survival rates at 2 and 5 years were 89 and 65%, respectively.
CONCLUSION: In stage-IV thymoma patients, weekly dose-dense chemotherapy offers similar activity to conventional regimens.
British Journal of Cancer (2009) 101, 1549–1554. doi:10.1038/sj.bjc.6605347 www.bjcancer.com
Published online 6 October 2009
& 2009 Cancer Research UK
Keywords: thymoma; chemotherapy; dose-dense; platinum; anthracycline; granulocyte colony-stimulating factor
                                                              
Thymoma is a rare thoracic tumour, but remains one of the most
common tumours originating in the mediastinum (Thomas et al,
1999; Giaccone, 2005; Girard et al, 2009). Clinical behaviour tends
to be indolent, but dissemination into the pleural space eventually
occurs and sometimes distant metastasis arise (Thomas et al,
1999). Thymoma is frequently associated with paraneoplastic
syndromes such as myasthenia gravis or pure red cell aplasia
(Thomas et al, 1999; Giaccone, 2005). No International Union
Against Cancer (UICC) TNM classification is available, and the
Masaoka classification has been widely used for clinical staging
(Masaoka et al, 1981; Girard et al, 2009).
The majority of thymomas are discovered at a limited stage,
representing Masaoka stage-I or II, and surgical resection is the
treatment of choice for such cases (Thomas et al, 1999; Giaccone,
2005; Girard et al, 2009). Even when the tumour invades
neighbouring organs, as stage-III disease, surgical resection with
postoperative radiotherapy is the preferred treatment when
complete resection can be achieved (Curran et al, 1988; Urgesi
et al, 1990; Ogawa et al, 2002; Strobel et al, 2004).
Systemic chemotherapy is usually used for stage-IVa (with
pleural or pericardial dissemination) or stage-IVb disease (with
lymphogenous or haematogenous metastases), but optimal manage-
ment is less well established (Thomas et al, 1999; Girard et al,
2009). Several reports have described favourable outcomes in
limited numbers of patients with stage-IVa disease treated using
multimodal treatment including surgery (Kim et al, 2004; Yokoi
et al, 2007).
Conversely, thymomas are generally reported to be chemo-
therapy-sensitive tumours, with response rates of 50–70% to
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scombination chemotherapy (Fornasiero et al, 1990; Loehrer et al,
1994, 1997, 2001; Giaccone et al, 1996; Berruti et al, 1999; Kim et al,
2004; Lucchi et al, 2006; Yokoi et al, 2007). Active agents include
cisplatin (CDDP), vincristine (VCR), doxorubicin (ADM), etopo-
side (ETP), cyclophosphamide (CPM) and ifosfamide (IFX).
Recent reports have shown marginal activity of pemetrexed
(Loehrer et al, 2006) and combined carboplatin and paclitaxel
(Lemma et al, 2008).
Dose-dense chemotherapy with the CODE combination
(CDDP–VCR–ADM–ETP) and addition of granulocyte colony-
stimulating factor (G-CSF) can be safely administered to patients
with advanced lung cancer (Murray et al, 1991; Fukuoka et al,
1997). Theoretically, this approach might be suitable for chemo-
sensitive tumours such as small-cell lung cancer and thymoma
(Goldie and Coldman, 1983, 1984; Levin and Hryniuk, 1987; Murray,
1987). Because some pilot data in Japan suggested that administra-
tion of 12 weeks of the CODE chemotherapy was barely feasible,
subsequent Japanese trials used a modified schedule, which was
shortened to 9 weeks (Fukuoka et al, 1997; Furuse et al,1 9 9 8 ) .
In 1996, the Japan Clinical Oncology Group (JCOG) initiated two
clinical trials for advanced thymoma: one aimed at evaluating the
safety and efficacy of the CODE regimen in stage IV, disseminated
thymoma (JCOG 9605), and the other aimed at evaluating the
safety and efficacy of CODE combination chemotherapy followed
by surgical resection and postoperative radiotherapy in initially
unresectable stage-III thymoma (JCOG 9606). The primary end-
point in each study was progression-free survival (PFS). The
results of JCOG 9605 are reported herein.
PATIENTS AND METHODS
Eligibility criteria
Patients with chemotherapy-naive, histologically documented
thymoma at Masaoka stage IVa or IVb were eligible for entry into
the study. Thymoma must have been confirmed histologically and
thymic tumours with other histology, such as thymic carcinoma,
carcinoid or lymphoma, were excluded. Each patient was required
to fulfil the following criteria: age, 15–70 years; Eastern Cooperative
Oncology Group (ECOG) performance status (PS), 0–2; adequate
organ function, that is, leukocyte count X4000ml
 1, platelet count
X10
5ml
 1, hemoglobin X10.0gdl
 1,s e r u mc r e a t i n i n eo1.5mg
dl
 1, creatinine clearance X60mlmin
 1,s e r u mb i l i r u b i no1.5mg
dl
 1, serum alanine transaminase and aspartate transaminase levels
less than double the upper limit of the institutional normal
range; and PaO2 X70mmHg. Exclusion criteria included un-
controlled heart disease, uncontrolled diabetes or hypertension,
pulmonary fibrosis or active pneumonitis as evidenced on chest
radiography, infections necessitating systemic use of antibiotics,
disease necessitating emergency radiotherapy such as superior vena
cava obstruction syndrome, active concomitant malignancy and
women who were pregnant or lactating. Also excluded were those
patients with grave complications of thymoma, such as pure red cell
aplasia or hypogammaglobulinemia. Myasthenia gravis was allowed
and these patients were not excluded per se.
Patient eligibility was confirmed by the JCOG Data Center
before patient registration. This study protocol was approved by
the institutional review board at each participating centre and
written informed consent was obtained from all patients prior to
enrolment.
Treatment Plan
Chemotherapy Patients received the 9-week CODE combination
chemotherapy as described below. Each chemotherapeutic agent
was administered intravenously.
Week 1: CDDP 25mgm
 2 on day 1 with antiemetics and ample
hydration; VCR (1mgm
 2) on day 1; ADM (40mgm
 2) on day 1
and ETP (80mgm
 2) on days 1–3.
Weeks 2, 4, 6 and 8: CDDP (25mgm
 2) on day 1 with
antiemetics and ample hydration and VCR (1mgm
 2) on day 1.
Weeks 3, 5, 7 and 9: CDDP (25mgm
 2) on day 1 with
antiemetics and ample hydration, ADM (40mgm
 2) on day 1 and
ETP (80mgm
 2) on days 1–3.
Each week, G-CSF (filgrastim (50mgm
 2day
 1) or lenograstim
(2mgkg
 1day
 1)) was administered by subcutaneous injection,
except on days when chemotherapy was administered or when
leukocyte count was X10000ml
 1. Corticosteroid was used only as
part of the antiemetic regimen, and the specific drug and dosage
were not regulated by the protocol.
Dose and schedule modifications were performed as follows:
when leukocyte count decreased to o2,000ml
 1 or platelet count
decreased to o50000ml
 1, chemotherapy was delayed by 1 week.
If PS decreased to 3–4 or temperature reached X38.01C, therapy
was likewise delayed for 1 week. No dose modification of
chemotherapy drugs was adopted for toxicity.
Post-protocol therapy
Surgery or radiotherapy was allowed after the completion of
chemotherapy, at the discretion of the attending physician, even in
the absence of apparent tumour regrowth. Conversely, additional
chemotherapy without evidence of disease progression was not
allowed.
Post-treatment after disease progression was not limited by the
study protocol.
Patient evaluation and follow-up
Before enrolment into the study, each patient underwent complete
medical history taking and physical examination (including
neurological check-up for signs of myasthenia gravis), determina-
tion of blood cell counts, serum biochemistry testing, arterial
blood gas analysis, pulmonary function testing, electrocardio-
graphy, chest radiography, computed tomography (CT) of the
chest, CT or ultrasonography of the upper abdomen, whole-brain
CT or magnetic resonance imaging (MRI) and an isotope bone
scan. Blood-cell counts, serum biochemistry testing and chest
radiography were performed weekly during each course of
chemotherapy.
The toxicity of chemotherapy was evaluated according to the
JCOG Toxicity Criteria (Tobinai et al, 1993), modified from
version 1 of the National Cancer Institute Common Toxicity
Criteria (NCI-CTC). Tumour responses were assessed radio-
graphically according to the standard, two-dimensional WHO
criteria (Miller et al, 1981), and were classified as complete
response (CR), partial response (PR), no change (NC), progressive
disease (PD) or non-evaluable (NE). After completion of the
protocol therapy, patients were followed up with periodic
re-evaluation, including chest CT every 6 months for the first 2
years and annually thereafter.
Central review
Radiographic reviews for the eligibility of enrolled patients and
clinical responses were performed at the time of the study
group meeting, held every 3–4 months. The study coordinator
(H Kunitoh) and a few selected investigators from the group
reviewed the radiographic films. The clinical response data
presented below were all confirmed by this central review. Reviews
of pathological specimens were not performed, because of
insufficient logistics of the study group at the time of the study
activation in 1997.
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The primary endpoint in each study was PFS. Due the rarity of the
tumour and the accrual reported in US trials, which required 10
years to register 26 patients with locally advanced (stage-III)
disease (Loehrer et al, 1997) and 9 years for 31 patients with
disseminated (stage-IV) disease (Loehrer et al, 1994), we presumed
we would be capable of accruing 30 patients in the target accrual
period of 4 years. The sample size was, therefore, not determined
based on statistical calculations. The expected PFS for the JCOG
9605 study was 2 years, which would give a 95% confidence
interval of 1.3–3.0 years with 30 cases.
The initial study design thus envisioned enrolment of 30 fully
eligible cases over 3 years for the study, with a follow-up period of
2 years.
Secondary endpoints included toxicity and safety, objective
tumour response to chemotherapy, pattern of relapse, and overall
survival (OS).
Progression-free survival and OS were calculated from the
date of enrolment and estimated using the Kaplan–Meier
method. Progression-free survival was censored at the last date
verifiable as progression-free, and OS was censored as of the date
of last follow-up. During the accrual period, an interim analysis
for futility was planned after half of the patients had been
registered and followed for X3 months. All analyses were
performed using SAS software version 8.2/9.1 (SAS Institute, Cary,
NC, USA).
RESULTS
Patient characteristics
A total of 30 patients from seven institutions were enrolled from
July 1997 to March 2004. Three patients were later found ineligible
due to wrong histology, with two cases of thymic carcinoma and
one case of carcinoid. These mistakes occurred due to technical
problems in the patient registry. Since the ineligible cases did
receive the protocol therapy, all 30 patients were analysed for
characteristics and toxicity. Twenty-seven eligible patients were
analysed for clinical response and survival (PFS and OS). Patient
characteristics are shown in Table 1.
Chemotherapy delivery and toxicity
Nine weeks of chemotherapy were performed for 26 of the original
30 patients (87%). The other four patients included one patient
receiving 7 weeks, two receiving 6 weeks and one receiving 3 weeks
of therapy. Median duration of chemotherapy for the 26 patients
who underwent the planned nine cycles was 10 weeks (range, 9–12
weeks).
Table 2 summarises the major toxicities of chemotherapy, which
were mainly haematological. Although 70% of patients experienced
grade-IV neutropenia, this was generally transient and rarely
complicated by infection/fever. Overall, toxicities were well
tolerated and no deaths due to toxicity occurred.
Other and late complications
Four patients showed thymoma-related complications. One patient
suffered from myasthenia gravis crisis occurring during chemo-
therapy, but subsequently recovered. Another patient showed
newly diagnosed myasthenia gravis 2.5 years after completion of
the protocol therapy, and thymectomy and resection of the
residual tumour were performed. Two other cases had pure red
cell aplasia occurring later in the clinical course with disease
progression of the thymomas.
Clinical response to chemotherapy
Clinical responses of the 27 eligible patients to chemotherapy were
judged radiologically and confirmed by central review. Responses
were as follows: CR, 0 patients; PR, 16 patients; NC, 10 patients and
PD, 1 patient. Overall response rate was 59% (95% confidence
interval, 39–78%).
Table 1 Patient characteristics
Item
Sex
Male/female 16/14
Age (years)
Median/range 47.5/29–69
ECOG performance status
PS0/PS1/PS2 11/18/1
Masaoka stage
IVa/IVb 22/8
Smoking history
No 9
Yes (median pack–years) 21 (22)
Myasthenia gravis
No/yes 28/2
Histology: thymoma and eligible 27
Lymphocyte predominance 12
Mixed cell 9
Epithelioid cell 4
Clear cell 1
Spindle cell 0
Unclassified 1
Histology: not thymoma (ineligible) 3
Carcinoma 2
Carcinoid 1
Lymphoma 0
Prior therapy
None 26
Surgery 2
Surgery and radiation 2
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; PS¼performance
status.
Table 2 Toxicity of chemotherapy (n¼30)
Toxicity Grades 1/2 Grade 3 Grade 4 %Grade 3/4
Leukopenia 3/6 12 8 67
Neutropenia 3/1 5 21 87
Anemia 0/5 25 ND 83
Thrombocytopenia 4/6 5 3 27
ALT 9/0 0 0 0
Creatinine 2/1 0 0 0
PaO2 9/2 0 0 0
Emesis 13/11 2 ND 7
Diarrhoea 4/2 0 0 0
Stomatitis 4/3 0 0 0
Constipation 3/4 2 0 7
Neuropathy 11/2 0 ND 0
Infection 3/4 3 0 10
Abbreviations: ALT¼alanine transaminase; ND¼not defined (the JCOG toxicity
criteria did not define grade IV in these toxicities).
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Post-protocol local therapy was administered to 18 of the 27
eligible patients (67%). Eight patients (all with stage-IVa disease)
underwent surgical resection and 13 patients (nine with stage-IVa
disease and four with stage-IVb disease) received thoracic radio-
therapy, with three patients receiving both. Whether patients
received local therapy after disease progression was not recorded
on case report forms.
After disease progression, 16 of the 27 patients (59%) received
additional chemotherapy. Post-protocol chemotherapy included
platinum re-challenge, irinotecan, taxanes and investigational
agents. Clinical response data to those therapies are not available.
PFS and OS
Survival data were finally updated in March 2006, 2 years after
accrual of the last patient. Figure 1 shows PFS and OS curves of the
27 eligible patients. Median PFS was 0.79 years (95% confidence
interval, 0.52–1.40 years) and PFS at 1 and 2 years was 37 and
15%, respectively. Median OS was 6.1 years and OS at 2 and 5 years
was 89 and 65%, respectively.
Overall survival was longer for stage-IVa patients than for
stage-IVb patients (Figure 2, median, 6.8 years and 3.5 years,
respectively), but PFS was similar (Figure 3, median, 0.79 years for
IVa patients and 0.78 years for IVb patients).
Pattern of relapse
As of the data cut-off, 26 of the 27 eligible patients had experienced
tumour relapse. Sites of initial relapse comprised the primary site
only in seven cases (27%), pleural or pericardial dissemination
in seven cases (27%) and primary site and pleural/pericardial
dissemination in nine cases (35%). Thus, 23 of the 26 patients with
relapse initially showed regrowth of the primary and/or pleural or
pericardial dissemination, with only three patients (12%) showing
initial relapse at distant organs.
DISCUSSION
Few prospective trials of chemotherapy have been described for
patients with advanced thymoma. Most prior studies have
combined stage-III, localised disease and stage-IV, disseminated
disease (Table 3). In addition, most have also included both
thymoma and thymic carcinoma histology.
We have reported results for patients with stage-IV disease, for
which systemic therapy should be the first choice. Among previous
studies, only those from the ECOG separately reported results for
stage-III and stage-IV patients (Loehrer et al, 1994, 1997). The
ECOG took 9 years to accrue 31 patients with stage-IV disease,
including patients with thymic carcinoma (Loehrer et al, 1994).
We prospectively accrued patients with thymoma only and
excluded thymic carcinoma, as thymoma and thymic carcinoma
clearly differ in clinical presentation and prognosis, and trials
involving these pathologies should, thus, be reported separately
(Eng et al, 2004; Giaccone, 2005; Lemma et al, 2008).
Trials of systemic chemotherapy for thymoma have reported
response rates of 50–90%, so this tumour is generally considered
sensitive to chemotherapy (Thomas et al, 1999). Dose-dense
chemotherapy such as the CODE four-drug combination has been
argued to be theoretically suitable for the treatment of such
chemosensitive tumours (Murray, 1987).
Although our results showed that dose-dense CODE chemo-
therapy could be safely administered to thymoma patients, efficacy
was not remarkable. The overall response rate was about 60%, no
different from prior reports employing conventional-dose
chemotherapy (Table 3). Progression-free survival was 9 months,
falling far short of the expected 2 years. Although OS studies
compared favourably with the corresponding ECOG trial (Loehrer
et al, 1994), attempting to reach a valid conclusion would be
difficult due to the small sample sizes. In addition, OS could be
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Figure 1 Progression-free survival and OS of the 27 eligible patients.
IVa (n=21) IVb (n=6)
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Year
0123456789 1 0 1 1
Figure 2 Overall survival according to Masaoka stage (stage IVa vs IVb).
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with stage-IVa disease, as combined therapy trial including stage-
IVa patients suggested (Kim et al, 2004). In fact, this might be one
reason why OS of stage-IVa patients was much longer than that of
stage-IVb patients, whereas PFS was similar.
It could be argued that shortened CODE chemotherapy, used
in Japan due to feasibility problem, led to inadequate results due
to insufficient total dosages of chemotherapy drugs. However,
another intensive chemotherapy, ETP–IFX–CDDP (VIP)
supported by G-CSF, has also reported disappointingly low response
rates and no better survival (Loehrer et al, 2001). Hanna et al (2001)
reported five patients with prior chemotherapy treated with high-
dose chemotherapy and stem cell support, but concluded that no
superiority to conventional therapy was evident. Taken together
with our results, intensification of chemotherapy does not appear
sufficiently promising for treating advanced thymoma.
Many prior chemotherapy studies have included platinum and
anthracyclines in their regimens. Non-anthracycline approaches
contained regimens such as VIP (Loehrer et al, 2001), ETP–CDDP
(Giaccone et al, 1996) and paclitaxel–carboplatin (Lemma et al,
2008) tended to yield lower response rates of 32–56% as compared
with regimens including anthracycline (Table 3). It might, thus, be
suggested that both anthracycline and platinum should, thus, be
included in thymoma chemotherapy, at least in current clinical
practice.
Favourable results have recently been reported with multi-
modality therapy, including surgical resection of stage-IVa disease
(Kim et al, 2004; Yokoi et al, 2007). In fact, about two-thirds of
eligible patients in our trial received local therapy after
chemotherapy, including surgery in eight patients. This could
have affected the outcome of the patients, as discussed above.
However, small sample size and patient selection preclude
reaching any definitive conclusion. When and what local therapy,
if any, would benefit patients with disseminated thymoma, remains
yet to be established. Further studies are warranted.
The present study shows several additional limitations. One is
that we did not perform a central review of histology, and, thus,
could not provide WHO classifications of histology (Okumura
et al, 2002; Travis et al, 2004). This makes comparisons with
results from other reports difficult. Central pathology review and
preferably tissue collection would be very important in future
trials.
In addition, due to the shorter-than-expected PFS, the planned
CT scan interval of every 6 months might not have accurately
evaluated PFS (Freidlin et al, 2007). Future trials might require
more frequent scans.
In conclusion, we have reported that weekly dose-dense
chemotherapy can be safely administered to patients with
thymoma. However, efficacy seems similar to that in patients
treated with conventional doses. More research on optimal
systemic therapy and the role of local modalities would appear
to be necessary.
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